NASDAQ · MRSN
Mersana Therapeutics, Inc.
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
Loading market information…
NASDAQ · RNTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Rein Therapeutics Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rein Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Dec 31, 2024 |
| -$1.89-310.68% vs estimate |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$0.27-8.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
$7.29$0.00 (0.0%)
Kezar Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.44% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$0.54+$0.01 (+1.34%)
HeartBeam, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.53% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
$2.98+$0.01 (+0.34%)
111, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.32% below the high.
$2.44+$0.07 (+2.95%)
Quantum BioPharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 81.75% below the high.
$0.53-$0.01 (-1.24%)
Tempest Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.12% below the high.
